BIO Notebook: Sanofi Hunts For Later-Stage Assets; Orphan Drug Sponsors Hunt For Legislative Fixes
Also, Novavax looks to turn its also-ran vaccine into a contender by banking on tolerability as government support recedes and the US COVID market goes commercial.
You may also be interested in...
CBER’s Marks said US FDA is working with Novavax on manufacturing to allow its protein-based vaccine to be ready for a fall roll-out. After some concerns about international coordination, multiple regulators seem to be settling on a monovalent approach for fall vaccinations.
US CDC is starting to prepare for the transition of COVID vaccine deliver to more traditional commercial channels. It is noteworthy that the first discussion of what will change did not include any talk of prices.
Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.